Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 4/20 | 0.50 |
| ▸ | MAX | P61244 | 4/20 | 0.50 |
| ▸ | EP300 | Q09472 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803105 | 0.85 | AR (0.53) | MYCMAXHIF1ATSHRXDH | |
| SCHEMBL2802978 | 0.84 | TSHR (0.42) | MYCMAXEP300TSHRCA12 | |
| SCHEMBL28607405 | 0.83 | PTPN11 (0.51) | MYCMAXEP300RXRARXRB | |
| SCHEMBL15660519 | 0.83 | MYC (0.54) | MYCMAXEP300RXRARXRB | |
| SCHEMBL1932820 | 0.82 | TSHR (0.66) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL25484510 | 0.81 | RXRA (0.68) | MYCMAXEP300RXRARXRB | |
| SCHEMBL17908022 | 0.81 | TSHR (0.69) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL22442386 | 0.81 | MYC (0.50) | MYCMAXEP300RXRARXRB | |
| SCHEMBL23793332 | 0.81 | MYC (0.53) | MYCMAXEP300RXRARXRB | |
| SCHEMBL4275354 | 0.81 | CA12 (0.67) | MYCMAXTSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | MYC 1809/4885MAX 2238/4885EP300 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.